Rheumatoid arthritis and other autoimmune disorders are associated with altered activity of the immunomodulatory enzyme IDO. However, the precise contributions of IDO function to autoimmunity remain unclear. In this article, we examine the effect of two different IDO enzymes, IDO1 and IDO2, on the development of autoimmune arthritis in the KRN preclinical model of rheumatoid arthritis. We find that IDO2, not IDO1, is critical for arthritis development, providing direct evidence of separate in vivo functions for IDO1 and IDO2. Mice null for Ido2 display decreased joint inflammation relative to wild-type mice owing to a reduction in pathogenic autoantibodies and Ab-secreting cells. Notably, IDO2 appears to specifically mediate autoreactive responses, but not normal B cell responses, as total serum Ig levels are not altered and IDO2 knockout mice are able to mount productive Ab responses to model Ags in vitro and in vivo. Reciprocal adoptive transfer studies confirm that autoantibody production and arthritis are modulated by IDO2 expression in a cell type extrinsic to the T cell. Taken together, our results, provide important insights into IDO2 function by defining its pathogenic contributions to autoantibody-mediated autoimmunity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947779PMC
http://dx.doi.org/10.4049/jimmunol.1303012DOI Listing

Publication Analysis

Top Keywords

ido2
9
autoantibody production
8
autoimmune arthritis
8
rheumatoid arthritis
8
ido1 ido2
8
arthritis
6
ido2 critical
4
critical mediator
4
mediator autoantibody
4
production inflammatory
4

Similar Publications

Alzheimer's disease-specific transcriptomic and epigenomic changes in the tryptophan catabolic pathway.

Alzheimers Res Ther

November 2024

Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences (FHML), Mental Health and Neuroscience Research Institute (MHeNs) and European Graduate School of Neuroscience (EURON), Maastricht University, Maastricht, 6211 LK, the Netherlands.

Background: Neurodegenerative disorders, including Alzheimer's disease (AD), have been linked to alterations in tryptophan (TRP) metabolism. However, no studies to date have systematically explored changes in the TRP pathway at both transcriptional and epigenetic levels. This study aimed to investigate transcriptomic, DNA methylomic (5mC) and hydroxymethylomic (5hmC) changes within genes involved in the TRP and nicotinamide adenine dinucleotide (NAD) pathways in AD, using three independent cohorts.

View Article and Find Full Text PDF
Article Synopsis
  • Substance use disorder (SUD) is a major public health issue in the U.S., linked to rising overdose deaths and prescription drug misuse, highlighting the need to explore its molecular and genetic roots.
  • The study utilized the All of Us cohort to analyze genetic variants in four genes related to the kynurenine pathway across six groups, including various types of substance use disorders.
  • Results indicated significant genetic variations in 14 out of 18 polymorphisms, with the cocaine group showing the highest number of significant variants, suggesting possible genetic predictors for increased susceptibility to SUD.
View Article and Find Full Text PDF

The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2).

Cells

November 2024

Section of Pharmacology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.

Indoleamine 2,3-dioxygenase 1 () and originated from gene duplication before vertebrate divergence. While IDO1 has a well-defined role in immune regulation, the biological role of IDO2 remains unclear. Discovered in 2007, is located near the gene.

View Article and Find Full Text PDF

Gene expression of kynurenine pathway enzymes in depression and following electroconvulsive therapy.

Acta Neuropsychiatr

October 2024

Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences & Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland.

Article Synopsis
  • This study explored how the expression of kynurenine pathway (KP) enzymes in the blood is affected in patients with depression compared to healthy controls and post-electroconvulsive therapy (ECT).
  • Results showed that certain KP enzymes were lower in patients with depression, but these findings weren’t statistically significant after accounting for other factors; ECT didn't change KP enzyme expression.
  • The study suggests that further research is needed to see if KP measures can effectively help in diagnosing depression and predicting responses to antidepressant treatments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!